All In Biotech

Drug Trial Radar · NCT04905667

Single Dose Pharmacokinetic Study of GB221 in Comparison With Herceptin ®

A Single Center, Randomized, Blind, Parallel Controlled, Single Dose Pharmacokinetic Study of Recombinant Humanized Anti-HER-2 Monoclonal Antibody Injection GB221 in Comparison With Herceptin ® in Chinese Healthy Adult Volunteers

Last checked: Nov 19, 2026Latest source record: May 27, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

87

Actual

Start

Nov 13, 2019

Primary completion

Sep 8, 2020

Study completion Sep 11, 2020

Sponsor

Lead sponsor
Genor Biopharma Co., Ltd.Industry
Sponsor type
Industry
First posted
May 27, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a single center, randomized, blind, parallel controlled clinical trial. The primary objective is to evaluate the single dose pharmacokinetics of recombinant Humanized anti-HER-2 monoclonal antibody injection GB221 in comparison with Herceptin ® in Chinese healthy adult volunteers. The main aim is to study the pharmacokinetic similarity between GB221 and Herceptin ®.

Conditions

  • Breast Cancer

Interventions

  • GB221Drug

    6 mg/kg, single dose, intravenous infusion, 90-100 min

  • HerceptinDrug

    6 mg/kg, single dose, intravenous infusion, 90-100 min

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. AUC0-tTime frame: Day 43
  2. AUC0-∞Time frame: Day 43
  3. CmaxTime frame: Day 43

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The Fifth Affiliated Hospital of Guangzhou Medical University

    Guangzhou, Guangzhou, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.